FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity

JACC Cardiovasc Imaging. 2015 Apr;8(4):493-494. doi: 10.1016/j.jcmg.2014.06.021. Epub 2014 Nov 12.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Atherosclerosis / diagnostic imaging*
  • Atherosclerosis / drug therapy*
  • Biomarkers / blood
  • Double-Blind Method
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Lipoproteins, LDL / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals
  • Recombinant Proteins

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Lipoproteins, LDL
  • MLDL1278A
  • Radiopharmaceuticals
  • Recombinant Proteins
  • oxidized low density lipoprotein
  • Fluorodeoxyglucose F18